{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:31:42Z","timestamp":1793320302546,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This open-label, non-comparative, 2:1 randomized, phase II trial (NCT03275506) in women with stage IIIC\/IV high-grade serous carcinoma (HGSC) for whom upfront complete resection was unachievable assessed whether adding pembrolizumab (200\u2009mg every 3 weeks) to standard-of-care carboplatin plus paclitaxel yielded a complete resection rate (CRR) of at least 50%. Postoperatively patients continued assigned treatment for a maximum of 2 years. Postoperative bevacizumab was optional. The primary endpoint was independently assessed CRR at interval\u00a0debulking surgery. Secondary endpoints were Completeness of Cytoreduction Index (CCI) and peritoneal cancer index (PCI) scores, objective and best response rates, progression-free survival, overall survival, safety, postoperative morbidity, and pathological complete response. The CRR in 61 pembrolizumab-treated patients was 74% (one-sided 95% CI\u2009=\u200963%), exceeding the prespecified \u226550% threshold and meeting the primary objective. The CRR without pembrolizumab was 70% (one-sided 95% CI\u2009=\u200954%). In the remaining patients CCI scores were \u22653 in 27% of the standard-of-care group and 18% of the investigational group and CC1 in 3% of the investigational group. PCI score decreased by a mean of 9.6 in the standard-of-care group and 10.2 in the investigational group. Objective response rates were 60% and 72%, respectively, and best overall response rates were 83% and 90%, respectively. Progression-free survival was similar with the two regimens (median 20.8 versus 19.4 months in the standard-of-care versus investigational arms, respectively) but overall survival favored pembrolizumab-containing therapy (median 35.3 versus 49.8 months, respectively). The most common grade \u22653 adverse events with pembrolizumab-containing therapy were anemia during neoadjuvant therapy and infection\/fever postoperatively. Pembrolizumab was discontinued prematurely because of adverse events in 23% of pembrolizumab-treated patients. Combining pembrolizumab with neoadjuvant chemotherapy is feasible for HGSC considered not completely resectable; observed activity in some subgroups justifies further evaluation to improve understanding of the role of immunotherapy in HGSC.<\/jats:p>","DOI":"10.1038\/s41467-024-46999-x","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T06:08:28Z","timestamp":1721110108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-8306","authenticated-orcid":false,"given":"Isabelle L.","family":"Ray-Coquard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude-Marie","family":"Savoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Schiffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6981-1678","authenticated-orcid":false,"given":"Marie-Ange","family":"Mouret-Reynier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olfa","family":"Derbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Kalbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"LeHeurteur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Cornila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Bengrine Lefevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Priou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9543-0729","authenticated-orcid":false,"given":"Nicolas","family":"Cloarec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Venat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7016-5383","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Selle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6182-6998","authenticated-orcid":false,"given":"Dominique","family":"Berton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Collard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Coquan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-323X","authenticated-orcid":false,"given":"Olivia","family":"Le Saux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Treilleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gouerant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4876-918X","authenticated-orcid":false,"given":"Antoine","family":"Angelergues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tredan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"key":"46999_CR1","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote, I. et al. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363, 943\u2013953 (2010).","journal-title":"N. Engl. J. Med."},{"key":"46999_CR2","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","volume":"19","author":"I Vergote","year":"2018","unstructured":"Vergote, I. et al. EORTC; MRC CHORUS study investigators. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 19, 1680\u20131687 (2018).","journal-title":"Lancet Oncol."},{"key":"46999_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe, S. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386, 249\u2013257 (2015).","journal-title":"Lancet"},{"key":"46999_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","volume":"59","author":"A Fagotti","year":"2016","unstructured":"Fagotti, A. et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur. J. Cancer 59, 22\u201333 (2016).","journal-title":"Eur. J. Cancer"},{"key":"46999_CR5","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","volume":"30","author":"A Fagotti","year":"2020","unstructured":"Fagotti, A. et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int. J. Gynecol. Cancer 30, 1657\u20131664 (2020).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"46999_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn, A. et al. ESMO Guidelines Committee. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 883\u2013848 (2023).","journal-title":"Ann. Oncol."},{"key":"46999_CR7","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","volume":"34","author":"AA Wright","year":"2016","unstructured":"Wright, A. A. et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 34, 3460\u20133473 (2016).","journal-title":"J. Clin. Oncol."},{"key":"46999_CR8","doi-asserted-by":"publisher","first-page":"S725","DOI":"10.1016\/j.annonc.2021.08.1188","volume":"32","author":"M Rodrigues","year":"2021","unstructured":"Rodrigues, M. et al. Real-world clinical outcomes of patients with de novo advanced high-grade epithelial ovarian cancer eligible to niraparib maintenance in France. Ann. Oncol. 32, S725\u2013S772 (2021).","journal-title":"Ann. Oncol."},{"key":"46999_CR9","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","volume":"23","author":"I Vergote","year":"2022","unstructured":"Vergote, I. et al. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. Lancet Oncol. 23, e374\u2013e384 (2022).","journal-title":"Lancet Oncol."},{"key":"46999_CR10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","volume":"30","author":"N Colombo","year":"2019","unstructured":"Colombo, N. et al. ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann. Oncol. 30, 672\u2013705 (2019).","journal-title":"Ann. Oncol."},{"key":"46999_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejca.2016.09.036","volume":"70","author":"R Rouzier","year":"2017","unstructured":"Rouzier, R. et al. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial. Eur. J. Cancer 70, 133\u2013142 (2017).","journal-title":"Eur. J. Cancer"},{"key":"46999_CR12","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1136\/ijgc-2019-000256","volume":"29","author":"Y Garcia","year":"2019","unstructured":"Garcia, Y. et al. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer. Int J. Gynecol. Cancer 29, 1050\u20131056 (2019).","journal-title":"Int J. Gynecol. Cancer"},{"key":"46999_CR13","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","volume":"6","author":"J Liu","year":"2016","unstructured":"Liu, J. et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 6, 1382\u20131399 (2016).","journal-title":"Cancer Discov."},{"key":"46999_CR14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/2159-8290.CD-11-0314","volume":"2","author":"A Palaz\u00f3n","year":"2012","unstructured":"Palaz\u00f3n, A. et al. The HIF-1\u03b1 hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov. 2, 608\u2013623 (2012).","journal-title":"Cancer Discov."},{"key":"46999_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","volume":"6","author":"AR S\u00e1nchez-Paulete","year":"2016","unstructured":"S\u00e1nchez-Paulete, A. R. et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. 6, 71\u201379 (2016).","journal-title":"Cancer Discov."},{"key":"46999_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","volume":"141","author":"JR Webb","year":"2016","unstructured":"Webb, J. R., Milne, K., Kroeger, D. R. & Nelson, B. H. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol. Oncol. 141, 293\u2013302 (2016).","journal-title":"Gynecol. Oncol."},{"key":"46999_CR17","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","volume":"41","author":"SL Topalian","year":"2023","unstructured":"Topalian, S. L. et al. Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy. Cancer Cell 41, 1551\u20131566 (2023).","journal-title":"Cancer Cell"},{"key":"46999_CR18","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","volume":"22","author":"BJ Monk","year":"2021","unstructured":"Monk, B. J. et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 22, 1275\u20131289 (2021).","journal-title":"Lancet Oncol."},{"key":"46999_CR19","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","volume":"22","author":"E Pujade-Lauraine","year":"2021","unstructured":"Pujade-Lauraine, E. et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 22, 1034\u20131046 (2021).","journal-title":"Lancet Oncol."},{"key":"46999_CR20","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1200\/JCO.21.00306","volume":"39","author":"KN Moore","year":"2021","unstructured":"Moore, K. N. et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39). J. Clin. Oncol. 39, 1842\u20131855 (2021).","journal-title":"J. Clin. Oncol."},{"key":"46999_CR21","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.1200\/JCO.23.00529","volume":"41","author":"J-E Kurtz","year":"2023","unstructured":"Kurtz, J.-E. et al. Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase III ATALANTE\/ENGOT-ov29 trial. J. Clin. Oncol. 41, 4768\u20134778 (2023).","journal-title":"J. Clin. Oncol."},{"key":"46999_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","volume":"152","author":"A Varga","year":"2019","unstructured":"Varga, A. et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol. Oncol. 152, 243\u2013250 (2019).","journal-title":"Gynecol. Oncol."},{"key":"46999_CR23","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis, U. A. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann. Oncol. 30, 1080\u20131087 (2019).","journal-title":"Ann. Oncol."},{"key":"46999_CR24","doi-asserted-by":"publisher","first-page":"e003122","DOI":"10.1136\/jitc-2021-003122","volume":"9","author":"JB Liao","year":"2021","unstructured":"Liao, J. B. et al. Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates. J. Immunother. Cancer 9, e003122 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"46999_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","volume":"7","author":"E Zsiros","year":"2021","unstructured":"Zsiros, E. et al. Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial. JAMA Oncol. 7, 78\u201385 (2021).","journal-title":"JAMA Oncol."},{"key":"46999_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ygyno.2020.07.028","volume":"159","author":"EK Lee","year":"2020","unstructured":"Lee, E. K. et al. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: a phase 2 clinical trial. Gynecol. Oncol. 159, 72\u201378 (2020).","journal-title":"Gynecol. Oncol."},{"key":"46999_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ygyno.2022.08.005","volume":"167","author":"QD Thomas","year":"2022","unstructured":"Thomas, Q. D. et al. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: a retrospective study from the ESME national cohort. Gynecol. Oncol. 167, 11\u201321 (2022).","journal-title":"Gynecol. Oncol."},{"key":"46999_CR28","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","volume":"5","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos, P. A. et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 5, 1141\u20131149 (2019).","journal-title":"JAMA Oncol."},{"key":"46999_CR29","doi-asserted-by":"publisher","unstructured":"Le Saux O. et al. Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-024-47000-5 (2024).","DOI":"10.1038\/s41467-024-47000-5"},{"key":"46999_CR30","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","volume":"26","author":"B You","year":"2020","unstructured":"You, B. et al. CA-125 ELIMination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial. Clin. Cancer Res. 26, 4625\u20134632 (2020).","journal-title":"Clin. Cancer Res."},{"key":"46999_CR31","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1200\/JCO.22.01207","volume":"40","author":"B You","year":"2022","unstructured":"You, B. et al. Identification of patients with ovarian cancer experiencing the highest benefit from bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): the GOG-0218 validation study. J. Clin. Oncol. 40, 3965\u20133974 (2022).","journal-title":"J. Clin. Oncol."},{"key":"46999_CR32","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ygyno.2023.01.008","volume":"170","author":"G Ferron","year":"2023","unstructured":"Ferron, G. et al. Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: lessons from the GINECO double-blind randomized phase II CHIVA trial. Gynecol. Oncol. 170, 186\u2013194 (2023).","journal-title":"Gynecol. Oncol."},{"key":"46999_CR33","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn, A. et al. PRIMA\/ENGOT-OV26\/GOG-3012 Investigators: niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391\u20132402 (2019).","journal-title":"N. Engl. J. Med."},{"key":"46999_CR34","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard, I. et al. PAOLA-1 investigators. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416\u20132428 (2019).","journal-title":"N. Engl. J. Med."},{"key":"46999_CR35","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1097\/PAS.0000000000001105","volume":"42","author":"E Munari","year":"2018","unstructured":"Munari, E. et al. PD-L1 assays 22C3 and SP263 are not interchangeable in non-small cell lung cancer when considering clinically relevant cutoffs: an interclone evaluation by differently trained pathologists. Am. J. Surg. Pathol. 42, 1384\u20131389 (2018).","journal-title":"Am. J. Surg. Pathol."},{"key":"46999_CR36","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ejso.2006.03.002","volume":"32","author":"FN Gilly","year":"2006","unstructured":"Gilly, F. N. et al. Quantitative prognostic indices in peritoneal carcinomatosis. Eur. J. Surg. Oncol. 32, 597\u2013601 (2006).","journal-title":"Eur. J. Surg. Oncol."},{"key":"46999_CR37","first-page":"100811","volume":"8","author":"C Callens","year":"2023","unstructured":"Callens, C. et al. Validation study of the shallowHRDv2 assay for homologous recombination deficiency (HRD) detection in high-grade ovarian carcinomas (HGOC) in the first-line setting, from the phase III PAOLA-1\/ENGOT-ov25 trial. Ann. Oncol. 8, 100811\u2013100811 (2023).","journal-title":"Ann. Oncol."},{"key":"46999_CR38","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/sim.721","volume":"20","author":"RP A\u2019Hern","year":"2001","unstructured":"A\u2019Hern, R. P. Sample size tables for exact single-stage phase II designs. Stat. Med. 20, 859\u2013866 (2001).","journal-title":"Stat. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46999-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46999-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46999-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T06:09:34Z","timestamp":1721110174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46999-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["46999"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-46999-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,16]]},"assertion":[{"value":"24 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.L.R.-C. reports personal honoraria from Agenus, Blueprint, BMS, PharmaMar, Genmab, Pfizer, AstraZeneca, Roche, GSK, MSD, Deciphera, Mersana, Merck Sereno, Novartis, Amgen, MacroGenics, Tesaro, and Clovis; honoraria to her institution from GSK, MSD, Roche, and BMS; consulting\/advisory roles for AbbVie, Agenus, Advaxis, BMS, PharmaMar, Genmab, Pfizer, AstraZeneca, Roche\/Genentech, GSK, MSD, Deciphera, Mersana, Merck Sereno, Novartis, Amgen, Tesaro and Clovis; research grant\/funding from MSD, Roche and BMS (self) and MSD, Roche, BMS, Novartis, AstraZeneca and Merck Sereno (to institution); and travel support from Roche, AstraZeneca, and GSK. E.K. reports honoraria from AstraZeneca, Roche, Sanofi, Tesaro, and GSK; consulting\/advisory roles for AstraZeneca, Roche, Sanofi, Tesaro and GSK; speakers\u2019 bureau for AstraZeneca, Roche, Sanofi, Tesaro, and GSK; and research funding from AstraZeneca, Roche, Sanofi, Tesaro and GSK. M.L. reports consulting\/advisory roles for Pierre Fabre, GSK, and Daiichi; research funding from Veracyte; and travel\/accommodation\/expenses from Mundi Pharma, Pfizer, GSK, and MSD. L.B.L. reports travel\/accommodation\/expenses from Servier. F.P. reports consulting\/advisory role for AstraZeneca. F.S. reports honoraria from AstraZeneca, Clovis Oncology, MSD, GSK-Tesaro, and Sandoz (Novartis); consulting\/advisory roles for AstraZeneca, GSK-Tesaro and MSD; speakers\u2019 bureau for AstraZeneca, MSD, and GSK-Tesaro; and travel\/accommodation\/expenses from Roche, AstraZeneca, MSD, and GSK-Tesaro. E.C. reports the following, all for an immediate family member: employment with Sanofi; consulting\/advisory role for MSD, BMS, Ipsen, and AstraZeneca; speakers\u2019 bureau for BMS, Ipsen, AstraZeneca, and Janssen; research funding from Pfizer; and travel\/accommodation\/expenses from Janssen. O.L.S. reports honoraria from MSD and Clovis, and travel\/accommodation\/expenses from Eisai. A.A. reports honoraria from GlaxoSmithKline. F.J. reports honoraria from Clovis, Amgen, GSK, Ipsen, BMS, MSD, AstraZeneca, Astellas, Janssen and Bayer; consultancy from AstraZeneca, GSK, Janssen and Ipsen; travel\/accommodation\/expenses from Ipsen and GSK; participation on a data safety monitoring\/advisory board for GSK; and participation on the GINECO guidelines committee. O.T. reports honoraria from Roche, MSD\/Merck, Novartis\/Sandoz, Pfizer, Lilly, AstraZeneca, Daiichi Sankyo, Eisai, Pierre Fabre, Seagen, and Gilead, and research funding from Roche, MSD\/Merck and BMS. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5931"}}